title: Effect of CD147 monoclonal antibody on paclitaxel resistance in HCE1 multicellular spheroids.
abstract: OBJECTIVE
  To investigate the effect of CD147 monoclonal antibody (mAb) on the natural resistance to paclitaxel (TAX) in the human cervical cancer line (HCE1) multicellular spheroid (HCE1/MCS) model and if CD147 mAb can reverse the HCE1/MCS resistance to TAX.
  
  
  METHODS
  HCE1/MCS was obtained by liquid overlay and rotating technique. HCE1/MCS morphological changes were observed before or after the interference of CD147 mAb. The effects of TAX on HCE1/MCS (including inhibition ratio, IC50 and index of multicellular resistance) before or after CD147 mAb treatment were determined by the method of WST-1 and the inhibition ratio curve was mapped. Cell cycle and apoptosis were detected by flow cytometer (FCM). The expression of CD147 and P-gp of both HCE1/MC and HCE1/MCS was detected by immunocytochemistry.
  
  
  RESULTS
  HCE1/MCS was established successfully. CD147 mAb could inhibit HCE1/MCS from forming spheroids. CD147 mAb could enhance the sensitivity of HCE1/MCS to TAX. IC50 in different concentrations of CD147 mAb (5,10,20 μg/mL) HCE1/MCS group were (40.31 ± 3.73), (32.43 ± 1.56), and (30.69 ± 1.01) μg/mL. CD147 mAb resulted in G1/G0 arrest in HCE1/MCS. CD147 mAb of low concentrations (0-10 μg/mL) caused a dose-dependent inhibition of HCE1/MCS (P<0.05). Combined with TAX, CD147 mAb could also induce HCE1/MCS cell cycle arrest in both G1/S and G2/M stage. The expression of CD147 and P-gp was consistent in HCE1/MCS groups.
  
  
  CONCLUSIONS
  CD147 plays an important role in muliticellular resistance of cervical cancer and inhibition of CD147 can synergistically reverse the multicellular drug resistance (MCR) in cervical cancer. The MCR of HCE1/MCS mediated by CD147 is related to P-gp.
authors.affiliation: Department of Gynecology and Obstetrics, Second Xiangya Hospital, Central South University, Changsha 410011, China.
authors.forename: Yun
authors.initials: Y
authors.lastname: Hu
authors.forename: Yilin
authors.initials: Y
authors.lastname: Wu
mesh_terms: D000911:Antibodies, Monoclonal / Q000276:immunology*; D051926:Basigin / Q000276:immunology*; D002294:Carcinoma, Squamous Cell / Q000276:immunology / Q000473:pathology; D045744:Cell Line, Tumor; D019008:Drug Resistance, Neoplasm / Q000276:immunology*; D005260:Female; D006801:Humans; D017239:Paclitaxel / Q000494:pharmacology*; D018874:Spheroids, Cellular / Q000187:drug effects / Q000276:immunology; D014407:Tumor Cells, Cultured; D002583:Uterine Cervical Neoplasms / Q000276:immunology* / Q000473:pathology
chemical_list: D000911:Antibodies, Monoclonal; D051926:Basigin; D017239:Paclitaxel